Shelton Capital Management’s Intellia Therapeutics NTLA Stock Holding History

Shelton Capital Management’s Portfolio NTLA Stock Details NTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-66,500	Closed	-$3.72M	–	713
2022 Q3	$3.72M	Sell	66,500 -1,800	-3%	-$112K	0.18%	135
2022 Q2	$3.54M	Hold	68,300	–	–	0.16%	143
2022 Q1	$4.96M	Hold	68,300	–	–	0.18%	121
2021 Q4	$8.08M	Hold	68,300	–	–	0.29%	77
2021 Q3	$9.16M	Hold	68,300	–	–	0.36%	57
2021 Q2	$11.1M	Hold	68,300	–	–	0.42%	49
2021 Q1	$5.48M	Hold	68,300	–	–	0.19%	116
2020 Q4	$3.72M	Hold	68,300	–	–	0.17%	130
2020 Q3	$1.36M	Hold	68,300	–	–	0.06%	311
2020 Q2	$1.44M	Hold	68,300	–	–	0.08%	213
2020 Q1	$835K	Buy	68,300 +17,100	+33%	+$230K	0.06%	236
2019 Q4	$751K	Buy	51,200 +11,500	+29%	+$160K	0.04%	267
2019 Q3	$530K	Buy	39,700 +15,000	+61%	+$239K	0.03%	334
2019 Q2	$404K	Buy	24,700 +24,478	+11,026%	+$385K	0.02%	414
2019 Q1	$13K	Sell	222 -12,778	-98%	-$190K	0.05%	307
2018 Q4	$177K	Hold	13,000	–	–	0.01%	721
2018 Q3	$372K	Hold	13,000	–	–	0.02%	475
2018 Q2	$356K	Buy	+13,000	New	+$315K	0.02%	482

Other funds holding NTLA

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Shelton Capital Management's NTLA Position: Q4 2022 in Review

Shelton Capital Management sold out of Intellia Therapeutics (NTLA) in Q4 2022, closing a stake of 66,500 shares — an estimated $3.72M sold.

Shelton Capital Management first reported a position in NTLA in Q2 2018 and held it in 18 quarters. The position peaked at $11.1M in Q2 2021. 303 funds tracked by Wall St. Rank hold NTLA as of Q4 2022.

Shelton Capital Management reported no remaining Intellia Therapeutics position as of Q4 2022 after selling out during the quarter.
Shelton Capital Management sold 66,500 Intellia Therapeutics shares in Q4 2022, an estimated $3.72M.
Shelton Capital Management first reported a position in Intellia Therapeutics in Q2 2018 and held it in 18 quarters.
Shelton Capital Management's Intellia Therapeutics position peaked at $11.1M in Q2 2021.
303 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q4 2022.

Based on Shelton Capital Management's 13F filing for Q4 2022, filed 13 Feb 2023.